<DOC>
	<DOCNO>NCT00517621</DOCNO>
	<brief_summary>validation french version FACT-GOG/NTX use questionnaire evaluate incidence peripheral neurotoxicity patient treat ovarian cancer paclitaxel associate EPO .</brief_summary>
	<brief_title>Use FACT-GOG/NTX Questionnaire Peripheral Neurotoxicity &amp; Validation French Version This Questionnaire</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Femal patient age &gt; 18 year Histologically proven diagnosis cancer ovary , fallopian tube peritoneal patient whose disease progress relapse patient receive least line platinumbased chemotherapy patient whose treatment relapse envisage comprise paclitaxel patient receive EPO treatment anaemia ECOG performans status &lt; 2 life expectancy &gt; 16 week patient clearly give consent signing informed consent form prior participation peripheral neuropathy grade &gt; 2 history ischemic cardiopathy , congestive heart failure ( NYHA &gt; 2 ) , arrhythmia , hypertension significant valvulopathy abnormal biological value A therapy serious disease could involve risk patient interfere aim study patient pregnant , breast feeding use inadequate contraception concomitant therapy potentially neurotoxic drug concomitant inclusion another therapeutic trial could interfere aim study patient familial , sociological , geographical psychological condition could follow correctly</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Peritoneal cancer</keyword>
	<keyword>Relapse progression</keyword>
</DOC>